In a pre-proof of a forthcoming journal article, members of the European College of Neuropsychopharmacology (ECNP) including European Medicines Agency’s Chief Medical Officer, Steffen Thirstrup, discuss knowledge gaps “that may be imperative for a successful implementation of psychedelic drugs as medicines”. These knowledge gaps were identified at ECNP’s two-day New Frontiers meeting in Nice…

Source

Previous articleReflecting on Psychedelics in 2023
Next articlePsychedelic Funding & Public Markets in 2023